Department of Medicine, University of Massachusetts Medical School, Worcester, MA.
Pliant Therapeutics, Redwood City, CA.
Hepatology. 2019 Mar;69(3):1105-1121. doi: 10.1002/hep.30249. Epub 2019 Feb 12.
Kupffer cell and macrophage (MØ) activation contributes to steatosis, inflammation, and fibrosis in alcoholic liver disease (ALD). We found increased frequency of MØ, T cells, and expression of C-C chemokine receptor type 2 (Ccr2) and C-C chemokine receptor type 5 (Ccr5) in the livers of patients with ALD, and increased circulating chemokines, C-C chemokine ligand types 2 (CCL2), and C-C chemokine ligand types 5 (CCL5) in patients with alcoholic hepatitis. We hypothesized that inhibition of CCL2 signaling with the dual CCR2/5 inhibitor, cenicriviroc (CVC), would attenuate ALD. In a mouse model of ALD, liver injury (alanine aminotransferase [ALT]) and steatosis were prevented by CVC whether administered as "prevention" throughout the alcohol feeding or as "treatment" started after the development of ALD. Alcohol-induced increases in early liver fibrosis markers (sirius red, hydroxyproline, and collagen-1) were normalized by both modes of CVC administration. We found that prevention and treatment with CVC reversed alcohol-related increases in liver mRNA and protein expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and CCL2. CVC administration regimens prevented the increase in infiltrating MØ (F4/80 CD11b ) and reduced proinflammatory Ly6C MØ in livers of alcohol-fed mice. CVC increased liver T-cell numbers and attenuated Il-2 expression without an effect on CD69 or CD25 T-cell expression. In vitro, CVC inhibited CCL2-induced increases in hepatocyte fatty acid synthase (Fasn) and adipose differentiation-related protein (Adrp), whereas it augmented acyl-coenzyme A oxidase 1 (Acox-1), proliferator-activated receptor gamma co-activator alpha (Pgc1α) and uncoupling protein 2 expression, suggesting mechanisms for attenuated hepatocyte steatosis. We found that CCL2 and CCL5 sensitized hepatocytes to lipopolysaccharide-induced liver injury (TNF-α, ALT, and lactate dehydrogenase release). Alcohol feeding induced apoptosis (poly ADP-ribose polymerase [PARP] and caspase-3 [CASP-3] cleavage) and pyroptosis (gasdermin D [GSDMD] cleavage) in livers, and CVC prevented both of these forms of cell death. Conclusion: Together, our data demonstrate preclinical evidence for CCR2/CCR5 inhibition with CVC as a potent intervention to ameliorate alcohol-induced steatohepatitis and liver damage.
库普弗细胞和巨噬细胞(MØ)的激活导致酒精性肝病(ALD)中的脂肪变性、炎症和纤维化。我们发现 ALD 患者肝脏中 MØ、T 细胞的频率增加,并且 C-C 趋化因子受体 2(Ccr2)和 C-C 趋化因子受体 5(Ccr5)的表达增加,并且酒精性肝炎患者的循环趋化因子 C-C 趋化因子配体 2(CCL2)和 C-C 趋化因子配体 5(CCL5)增加。我们假设用双重 CCR2/5 抑制剂 cenicriviroc(CVC)抑制 CCL2 信号传导会减轻 ALD。在 ALD 的小鼠模型中,CVC 无论作为整个酒精喂养期间的“预防”还是在 ALD 发生后开始的“治疗”给药,都可以预防肝损伤(丙氨酸氨基转移酶[ALT])和脂肪变性。两种 CVC 给药方式均可使酒精诱导的早期肝纤维化标志物(天狼星红,羟脯氨酸和胶原蛋白-1)正常化。我们发现,CVC 的预防和治疗可逆转与酒精相关的肝 mRNA 和蛋白表达增加肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-6 和 CCL2。CVC 给药方案阻止了酒精喂养小鼠肝脏中浸润性 MØ(F4/80 CD11b)的增加,并减少了促炎 Ly6C MØ。CVC 增加了肝 T 细胞数量,并减轻了 Il-2 的表达,而对 CD69 或 CD25 T 细胞的表达没有影响。体外,CVC 抑制 CCL2 诱导的肝细胞脂肪酸合酶(Fasn)和脂肪分化相关蛋白(Adrp)增加,而增加酰基辅酶 A 氧化酶 1(Acox-1)、过氧化物酶体增殖物激活受体γ共激活因子-α(Pgc1α)和解偶联蛋白 2 的表达,提示减轻肝细胞脂肪变性的机制。我们发现 CCL2 和 CCL5 使肝细胞对脂多糖诱导的肝损伤(TNF-α、ALT 和乳酸脱氢酶释放)敏感。酒精喂养诱导肝脏细胞凋亡(多聚 ADP-核糖聚合酶[PARP]和半胱天冬酶-3[CASP-3]切割)和细胞焦亡(gasdermin D[GSDMD]切割),CVC 可预防这两种形式的细胞死亡。结论:综上所述,我们的数据提供了 CCR2/CCR5 抑制用 CVC 作为一种有效的干预措施来改善酒精性肝炎和肝损伤的临床前证据。